Synthesis and antitumor activity of 4- and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone

Tandem H/D Exchange-SET Reductive Deuteration Strategy for the Synthesis of α,β-Deuterated Amines Using D2O

α,β-Deuterated amines are crucial for the development of deuterated drugs. We intend to introduce the novel tandem H/D exchange-single electron transfer (SET) reductive deuteration strategy with high pot- and reagent-economy by the synthesis of α,β-deuterated amine using nitrile as the precursor. The H/D exchange of the -CH₂CN group was achieved by D₂O/Et₃N, which were also the required reagents in the tandem SmI₂-mediated SET reductive deuteration of the α-deuterated nitrile. The potential application of this method was further showcased by the synthesis of bevantolol-d₄.

A simple and efficient metal free, additive, or base free dehydrogenation of tetrahydroisoquinolines using oxygen as a clean oxidant

Metal free dehydrogenation of various substituted tetrahydroisoquinolines via a simple and convenient metal free, atom economical route for the synthesis of corresponding isoquinolines under oxygen atmosphere in N-methyl-2-pyrollidone (NMP) is described. Metal free dehydrogenation was carried out without the use of additive or base. A scope of the methodology was demonstrated for a number of aryl and heteroaryl substitutions present at C1 position and ester moiety at C3 position and was found to be good substrates. Substituted isoquinolines (3a–3h) and their esters (3i–3m) were synthesized in very good to excellent yields.

Copper-Catalyzed Benign and Efficient Oxidation of Tetrahydroisoquinolines and Dihydroisoquinolines Using Air as a Clean Oxidant

A green chemical method for mild oxidation of 1,2,3,4-tetrahydroisoquinolines (THIQs) and 3,4-dihydroisoquinolines (DHIQs) has been developed using air (O₂) as a clean oxidant. DHIQs and THIQs could be efficiently oxidized to isoquinolines in dimethyl sulfoxide at 25 °C under an open air atmosphere with CuBr₂ (20 mol %) as the catalyst; different bases [NaOEt and/or 1,8-diazabicyclo[5,4,0]undec-7-ene] were used for the reaction according to the patterns of substituents (R¹, R²).

System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]Isoquinoline Derivative as Anticancerous Drug Candidate Against it

Cancer is a public health concern which is spreading throughout the world. Different approaches have been employed to combat this disease. System biology approach has been used to understand the molecular mechanisms of drugs targeting cancer cell's receptor which have opened-up a window to develop effective drugs for it. We have demonstrated biomolecular interaction studies using the rational drug design of indole[2,1-a]isoquinoline derivative as a potent inhibitor against identified cancerous protein PIK3CA -a catalytic sub-unit of PI3K family protein-and compared its affinity with FDA approved drugs for receptors such as dactolisib, idelalisib, and several others such afatinib, avastin, ceritinib and crizotinib, etc.; by docking against potential receptor to set a cutoff value for our screening. Isoquinolines are small alkaloids with a vast variety of substitution depending upon their biogenetic pattern. Isoquinoline derivatives have been reported for their antimalarial, antibacterial, antifungal and anticancerous activities. The results obtained from the present studies conclude that membrane protein is an efficient drug that can be used to target cancer. Moreover, comparative study with ADMET prediction concludes that isoquinoline can be a potent drug for cancer treatment.

Short-Term Toxicological Evaluation of Triapine (3-Amino-Pyridine-2-Carboxaldehyde Thiosemicarbazone or 3-AP), a Ribonucleotide Reductase Inhibitor with Potential Antitumor Activity, in Dogs and Rats

The objective of these studies was to evaluate the potential toxicity of Triapine (a ribonucleotide reductase inhibitor with potential antitumor activity) in dogs and rats. Various doses (1–20 mg/kg) of Triapine were administered intravenously (IV), once daily for 1, 3, or 5 consecutive days, to Beagle dogs or Albino Sprague-Dawley rats. Control animals were treated with vehicle, with an amount equivalent to a dose of 20 mg/kg of Triapine. Data collected included body weights, clinical signs, clinical pathology (serum chemistry and hematology), and gross and microscopic pathology. In dogs, the no-observed-adverse-effect level (NOAEL) of Triapine, when administered once daily for 5 consecutive days, was 1 mg/kg. For 5 daily doses at 3 mg/kg, or a single dose at 10 mg/kg, Triapine induced only limited toxicity (emesis and diarrhea, causing inappetence and body weight loss). The intensities/frequencies of the clinical signs were greater when Triapine was administered over 15 minutes than 120 minutes. Ondansetron (an antiemetic agent due to its H2 antagonistic properties) delayed, but did not eliminate, emesis induced by 10 mg/kg of Triapine. In rats, the NOAEL of Triapine, when administered once daily for 5 consecutive days, was not determined. However, when administered once daily for 3 consecutive days, 1 mg/kg was considered the NOAEL. Five to 20 mg/kg of Triapine (and its vehicle) induced a wide-range of toxicity. Toxicity related to the vehicle (as reflected by the similar or greater intensity/frequency of these effects in vehicle-treated rats than Triapine-treated rats) were reduced activity, discolored urine, discolored tails, and the accompanying gross and histopathological findings. Triapine-related effects were mortality; reductions in total protein and albumin levels; reductions in red blood cell, white blood cell, and platelet counts; reductions in body and thymic weights; increases in the liver and lung weights (and the corresponding microscopic findings of these organs); and microscopic findings of the adrenal cortex, testes, bone marrow, and kidney. These effects generally increased in a dose-related manner between 5–15 mg/kg, and leveled off at 15 and 20 mg/kg. Essentially all effects induced by Triapine and/or vehicle had returned, or were returning, to normal during a 30-day recovery period. In conclusion, the NOAEL of Triapine was 1 mg/kg, when administered daily for 5 consecutive days, in dogs. Five daily doses at 3 mg/kg or a single dose at 10 mg/kg Triapine-induced emesis and diarrhea. The toxicity was greater when Triapine was administered over 15 minutes than over 120 minutes. Ondansetron had limited efficacy in attenuating the emetic effects of the high dose (10 mg/kg) of Triapine. In rats, the NOAEL of Triapine was 1 mg/kg when administered once daily for 3 consecutive days. At 5–20 mg/kg, Triapine induced a broad spectrum of toxicological effects, which is consistent with its ribonucleotide reductase inhibitory properties. Essentially all effects induced by Triapine and/or vehicle were reversible within 30 days.

Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity

The iron coordination and biological chemistry of a series of heterocyclic dithiocarbazate Schiff base ligands is reported with regard to their activity as Fe chelators for the treatment of Fe overload and also cancer. The ligands are analogous to tridentate heterocyclic hydrazone and thiosemicarbazone chelators we have studied previously which bear NNO and NNS donor sets. The dithiocarbazate Schiff base ligands in this work also are NNS chelators and form stable low spin ferric and ferrous complexes and both have been isolated. In addition an unusual hydroxylated ligand derivative has been identified via an Fe-induced oxidation reaction. X-ray crystallographic and spectroscopic characterisation of these complexes has been carried out and also the electrochemical properties have been investigated. All Fe complexes exhibit totally reversible Fe(III/II) couples in mixed aqueous solvents at potentials higher than found in analogous thiosemicarbazone Fe complexes. The ability of the dithiocarbazate Schiff base ligands to mobilise Fe from cells and also to prevent Fe uptake from transferrin was examined and all ligands were effective in chelating intracellular Fe relative to known controls such as the clinically important Fe chelator desferrioxamine. The Schiff base ligands derived from 2-pyridinecarbaldehyde were non-toxic to SK-N-MC neuroepithelioma (cancer) cells but those derived from the ketones 2-acetylpyridine and di-2-pyridyl ketone exhibited significant antiproliferative activity.

2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity

Through systematic structure-activity studies of the 2-benzoylpyridine thiosemicarbazone (HBpT), 2-(3-nitrobenzoyl)pyridine thiosemicarbazone (HNBpT) and dipyridylketone thiosemicarbazone (HDpT) series of iron (Fe) chelators, we identified structural features necessary to form Fe complexes with potent anticancer activity (J. Med. Chem. 2007, 50, 3716-3729). In this investigation, we generated the related 2-acetylpyridine thiosemicarbazone (HApT) analogues to examine the influence of the methyl group at the imine carbon. Four of the six HApT chelators had potent antitumor activity (IC(50): 0.001-0.002 microM) and Fe chelation efficacy that was similar to the most effective HBpT and HDpT ligands. The HApT Fe complexes had the lowest Fe(III/II) redox potentials of any thiosemicarbazone series we have generated. This property, in combination with their ability to effectively chelate cellular Fe, make the HApT series one of the most potent antiproliferative agents developed by our group.

Synthesis, cytotoxic and antimalarial activities of benzoyl thiosemicarbazone analogs of isoquinoline and related compounds

Thiosemicarbazone analogs of papaveraldine and related compounds 1–6 were synthesized and evaluated for cytotoxic and antimalarial activities. The cytotoxic activity was tested against HuCCA-1, HepG2, A549 and MOLT-3 human cancer cell lines. Thiosemicarbazones 1–5 displayed cytotoxicity toward all the tested cell lines, while compounds 2–5 selectively showed potent activity against the MOLT-3 cell lines. Significantly, N(4)-phenyl-2-benzoylpyridine thiosemicarbazone 4 exhibited the most potent activity against HuCCA-1, HepG2, A549 and MOLT-3 cell lines with IC₅₀ values of 0.03, 4.75, 0.04 and 0.004 µg/mL, respectively. In addition, 2-benzoylpyridine thio-semicarbazones 3 and 4 showed antimalarial activity against Plasmodium falciparum with IC₅₀ of 10^-7 to < 10^-6 M. The study demonstrates the quite promising activity of analog 4 as a lead molecule for further development.

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

Triapine is a novel small molecule ribonucleotide reductase inhibitor that showed activity in renal cell carcinoma (RCC) cell lines. Evaluating new agents with novel mechanisms remains of interest for patients with incurable RCC. This was a single-arm, multicentre phase II trial where Triapine was given at a schedule of 96 mg/m2 2-h infusion daily x 4 repeated every 2 weeks in patients with recurrent RCC. A median of four cycles of Triapine was administered to 19 eligible patients. One response was seen (7%.) Median time to progression was 3.6 months. Common adverse events (AEs) were grade 1-2, with fatigue in 74%, nausea in 68% and vomiting in 58%. However grade 3/4 neutropenia was seen in 79% and acute reactions of hypoxia, hypotension, methemoglobinemia were seen. Dose reductions/delays due to AEs were common with only 47% of patients receiving > 90% of planned dose intensity. The study closed, at the end of stage 1 as it did not meet the minimal efficacy criteria to proceed. Further evaluation of Triapine at this dose and schedule in patients with advanced kidney cancer is not recommended.

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies

Triapine, a potent inhibitor of ribonucleotide reductase, has demonstrated anti-leukemia activity in pre-clinical models. We conducted a Phase I study of Triapine administered as a 2 h infusion for 5 days in 25 adults with advanced leukemias. We established that Triapine at 96 mg/m2 once a day can be given safely on days 1-5 and 15-19 or 1-5 and 8-12 of a 4-week cycle. When administered twice a day on days 1-5 and 8-12, the maximum tolerated dose of Triapine appears to be 64 mg/m2, although the true criteria for DLT were not met by protocol definition. No CR or PR were observed, but 76% of patients had a >50% reduction in white blood cell counts. At all dose levels, the peak plasma concentration of Triapine (2.2-5.5 microM) was above levels required to achieve in vitro/in vivo leukemia growth inhibition. Based on these data, we conclude that Triapine warrants further investigation in hematologic malignancies.

Antimicrobial and mutagenic activity of some carbono- and thiocarbonohydrazone ligands and their copper(II), iron(II) and zinc(II) complexes

Several mono- and bis- carbono- and thiocarbonohydrazone ligands have been synthesised and characterised; the X-ray diffraction analysis of bis(phenyl 2-pyridyl ketone) thiocarbonohydrazone is reported. The coordinating properties of the ligands have been studied towards Cu(II), Fe(II), and Zn(II) salts. The ligands and the metal complexes were tested in vitro against Gram positive and Gram negative bacteria, yeasts and moulds. In general, the bisthiocarbonohydrazones possess the best antimicrobial properties and Gram positive bacteria are the most sensitive microorganisms. Bis(ethyl 2-pyridyl ketone) thiocarbonohydrazone, bis(butyl 2-pyridyl ketone)thiocarbonohydrazone and Cu(H2nft)Cl2 (H2nft, bis(5-nitrofuraldehyde)thiocarbonohydrazone) reveal a strong activity with minimum inhibitory concentrations of 0.7 microgram ml-1 against Bacillus subtilis and of 3 micrograms ml-1 against Staphylococcus aureus. Cu(II) complexes are more effective than Fe(II) and Zn(II) ones. All bisthiocarbono- and carbonohydrazones are devoid of mutagenic properties, with the exception of the compounds derived from 5-nitrofuraldehyde. On the contrary a weak mutagenicity, that disappears in the copper complexes, is exhibited by monosubstituted thiocarbonohydrazones.